Data analysis was done in accordance with the standards of the Cochrane Neonatal Review Group. Main Results: Eleven studies were identified that met inclusion criteria [nine without routine application of CPAP in the selective treatment group; two with routine application of CPAP in the selective treatment group]. The meta-analysis of studies conducted prior to the routine application of CPAP demonstrated a decrease in the risk of air leak and neonatal mortality associated with prophylactic administration of surfactant. However, the analyses of studies that allowed for routine stabilization on CPAP demonstrated a decrease in the risk of chronic lung disease or death in infants stabilized on CPAP. When all studies were evaluated together, the benefits of prophylactic surfactant could no longer be demonstrated (see fig. 1 ).
differences and demonstrate less risk of chronic lung disease or death when using early stabilization on CPAP with selective surfactant administration to infants requiring intubation. Rojas 
Commentary
Roger F. Soll, Burlington, Vt.
Things change. In the original systematic review of 'Prophylactic surfactant versus selective use of surfactant', nine trials were included. These trials were all done in the 1990s prior to the routine use of antenatal steroids and our attempts to routinely support infants on continuous distending pressure to maintain their functional residual capacity. Throughout the past decade, the use of antenatal steroids has more than tripled and more and more investigators are becoming comfortable with the early application of distending pressure to maintain functional residual capacity. In this context, there have been several trials looking at early stabilization on distending pressure compared to a more aggressive early surfactant therapy. Certain trials approached all infants at risk of RDS while others [1, 2] only evaluated infants who did not require intubation in the delivery room or looked well enough not to be placed on any respiratory support.
The updated analysis of Rojas-Reyes and colleagues includes the two trials from the NICHD network (SUP-PORT) [3] and the Vermont Oxford Network Delivery Room Management Study [4] . When these two studies that were conducted in the recent clinical context (with increased exposure to antenatal steroids and routine application of nasal CPAP to the control group) are included, no differences in important clinical outcomes emerge. In fact, when these two studies are combined with the nine studies from the 1990s, there are no longer clinically significant effects seen with prophylactic surfactant. When the two studies are evaluated on their own, there is a strong trend towards clinical improvement, specifically a reduction in the risk of BPD or death.
The day for routine aggressive prophylactic surfactant to all infants at risk of RDS has passed. Early stabilization with non-invasive modalities has taken its place. Selective use of surfactant, whether by intubation or other minimally invasive techniques, such as catheter insertion, will come to the fore. Further trials will be needed for us to understand specific issues regarding patient selection (e.g., steroid exposure vs. non-exposure) and the best techniques to administer surfactant in those infants who develop progressive respiratory distress.
